Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul T Edlefsen

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Plos Pathogens|February 7, 2020
Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and ThailandMorgane Rolland, Sodsai Tovanabutra, Bethany Dearlove, et al.
Science (New York, N.Y.)|May 25, 2013
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigmsScott G Hansen, Jonah B Sacha, Colette M Hughes, et al.
Nature|June 22, 2017
Addendum: Immune clearance of highly pathogenic SIV infectionScott G Hansen, Michael Piatak, Abigail B Ventura, et al.
Nature|September 13, 2013
Immune clearance of highly pathogenic SIV infectionScott G Hansen, Michael Piatak, Abigail B Ventura, et al.
Viruses|July 7, 2019
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy AssessmentRaabya Rossenkhan, Morgane Rolland, Jan P L Labuschagne, et al.
Plos Pathogens|August 22, 2024
Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistenceBenjamin Varco-Merth, Morgan Chaunzwa, Derick M Duell, et al.
Science Immunology|June 17, 2022
Myeloid cell tropism enables MHC-E-restricted CD8<sup>+</sup> T cell priming and vaccine efficacy by the RhCMV/SIV vaccineScott G Hansen, Meaghan H Hancock, Daniel Malouli, et al.
Science Immunology|March 26, 2021
Cytomegaloviral determinants of CD8<sup>+</sup> T cell programming and RhCMV/SIV vaccine efficacyDaniel Malouli, Scott G Hansen, Meaghan H Hancock, et al.
The Journal of Clinical Investigation|January 29, 2026
Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 reboundWere R Omange, Benjamin D Varco-Merth, Omo Fadeyi, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adultsJames J Kobie, Wilton B Williams, William O Hahn, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Plos Pathogens|February 7, 2020
Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and ThailandMorgane Rolland, Sodsai Tovanabutra, Bethany Dearlove, et al.
Science (New York, N.Y.)|May 25, 2013
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigmsScott G Hansen, Jonah B Sacha, Colette M Hughes, et al.
Nature|June 22, 2017
Addendum: Immune clearance of highly pathogenic SIV infectionScott G Hansen, Michael Piatak, Abigail B Ventura, et al.
Nature|September 13, 2013
Immune clearance of highly pathogenic SIV infectionScott G Hansen, Michael Piatak, Abigail B Ventura, et al.
Viruses|July 7, 2019
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy AssessmentRaabya Rossenkhan, Morgane Rolland, Jan P L Labuschagne, et al.
Plos Pathogens|August 22, 2024
Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistenceBenjamin Varco-Merth, Morgan Chaunzwa, Derick M Duell, et al.
Science Immunology|June 17, 2022
Myeloid cell tropism enables MHC-E-restricted CD8<sup>+</sup> T cell priming and vaccine efficacy by the RhCMV/SIV vaccineScott G Hansen, Meaghan H Hancock, Daniel Malouli, et al.
Science Immunology|March 26, 2021
Cytomegaloviral determinants of CD8<sup>+</sup> T cell programming and RhCMV/SIV vaccine efficacyDaniel Malouli, Scott G Hansen, Meaghan H Hancock, et al.
The Journal of Clinical Investigation|January 29, 2026
Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 reboundWere R Omange, Benjamin D Varco-Merth, Omo Fadeyi, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adultsJames J Kobie, Wilton B Williams, William O Hahn, et al.
Pageof 9